Five Prime Therapeutics Inc. (NASDAQ:FPRX) traded down 1.3% on Tuesday . The company traded as low as $44.15 and last traded at $44.49, with a volume of 184,733 shares trading hands. The stock had previously closed at $45.06.

A number of equities research analysts recently weighed in on the company. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Five Prime Therapeutics in a report on Tuesday. BMO Capital Markets assumed coverage on Five Prime Therapeutics in a report on Tuesday, April 12th. They set a “market perform” rating and a $50.00 price target for the company. Zacks Investment Research raised Five Prime Therapeutics from a “hold” rating to a “buy” rating and set a $46.00 price target for the company in a report on Tuesday, April 5th. Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and set a $48.00 price target on shares of Five Prime Therapeutics in a report on Thursday, May 19th. Finally, Jefferies Group reaffirmed a “buy” rating on shares of Five Prime Therapeutics in a report on Sunday, May 8th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $45.80.

The stock has a 50-day moving average of $42.46 and a 200-day moving average of $39.40. The company has a market cap of $1.16 billion and a price-to-earnings ratio of 4.85.

Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings results on Thursday, May 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.22. The company earned $6.50 million during the quarter, compared to the consensus estimate of $5.26 million. The company’s quarterly revenue was up 51.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.44) earnings per share. Equities research analysts anticipate that Five Prime Therapeutics Inc. will post ($2.35) earnings per share for the current fiscal year.

In related news, Director Franklin M. Berger purchased 6,090 shares of the business’s stock in a transaction that occurred on Tuesday, April 19th. The stock was acquired at an average cost of $47.06 per share, for a total transaction of $286,595.40. Following the completion of the purchase, the director now owns 77,890 shares in the company, valued at approximately $3,665,503.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Franklin M. Berger purchased 5,000 shares of the business’s stock in a transaction that occurred on Friday, April 22nd. The stock was bought at an average price of $49.47 per share, with a total value of $247,350.00. Following the completion of the purchase, the director now owns 81,980 shares of the company’s stock, valued at approximately $4,055,550.60. The disclosure for this purchase can be found here.

Several large investors recently modified their holdings of the stock. ProShare Advisors LLC boosted its stake in shares of Five Prime Therapeutics by 16.9% in the fourth quarter. ProShare Advisors LLC now owns 25,418 shares of the company’s stock valued at $1,055,000 after buying an additional 3,682 shares during the period. Oxford Asset Management purchased a new position in shares of Five Prime Therapeutics during the fourth quarter valued at approximately $1,241,000. Russell Frank Co purchased a new position in shares of Five Prime Therapeutics during the fourth quarter valued at approximately $1,265,000. EAM Investors LLC purchased a new position in shares of Five Prime Therapeutics during the fourth quarter valued at approximately $1,549,000. Finally, California State Teachers Retirement System increased its position in shares of Five Prime Therapeutics by 7.3% in the fourth quarter. California State Teachers Retirement System now owns 42,025 shares of the company’s stock valued at $1,744,000 after buying an additional 2,842 shares in the last quarter.

Five Prime Therapeutics, Inc (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.